Tonix has a robust pipeline of programs in development stages ranging from preclinical to preparing for NDA submission, across multiple therapeutic modalities and including both small molecules and biologics. Tonix also markets two FDA-approved products for acute migraine in adults.

Tonix’s pipeline is managed by a team of passionate professionals that are adept at advancing innovative programs into the clinic and throughout the various stages of development with the goal of FDA approval and marketing to those in need.

While many of Tonix’s product candidates are proprietary, in-house developments, it also has collaborations with government institutions, world-class academic and non-profit research organizations, as well as license agreements with other biotech companies.